Paweł Rajewski | Cardiovascular risk | Best Research Article Award | Best Research Article Award

🏥Current Position and Roles:

Dr. Paweł Rajewski is a distinguished medical doctor, professor, and the rector of the Faculty of Health Sciences at the University of Health Sciences in Bydgoszcz. He holds the vital role of Provincial Consultant in Infectious Diseases for the Kuyavian-Pomeranian Voivodeship, providing oversight and strategic insights on infectious disease management in the region. Dr. Rajewski serves as the Head of the Department of Internal Medicine and Infectious Diseases at the Tadeusz Browicz Provincial Infectious Disease Hospital in Bydgoszcz, as well as the Head of the Liver, Internal, Infectious, and Metabolic Disorders Clinic at CM Gizińscy in Bydgoszcz. Previously, he served as the Medical Director and Head of the Department of Internal Medicine and Hepatology at the Emil Warmiński Multispecialist City Hospital. Through these roles, he contributes to the health of countless patients while also shaping medical policy and practice.

🎓Academic Background:

Dr. Rajewski’s academic journey has been marked by an enduring commitment to medicine, specializing in areas such as internal medicine, infectious diseases, hepatology, and clinical transplantation. His qualifications in these areas form the bedrock of his clinical and academic expertise, enabling him to deliver high-impact research and patient care in fields that are central to public health. Dr. Rajewski’s education includes specialty certifications as a lipidologist, accredited by the Polish Lipid Association, and an obesitologist with certifications from the Polish Association for the Study of Obesity and the Polish Society for Obesity Treatment.

📚Research Interests and Publication Achievements: 

Dr. Rajewski has contributed over 200 articles, primarily focused on metabolic disorders, obesity, liver diseases, and cardiovascular risk factors. His work, published in reputed medical journals, has been instrumental in advancing knowledge on these critical health issues. His research sheds light on complex metabolic processes, influencing both preventive and therapeutic approaches to conditions like non-alcoholic fatty liver disease and atherosclerosis. His publications are widely recognized for their scientific rigor and relevance, contributing to his esteemed reputation in the medical research community.

🔬Ongoing Research Projects:

Dr. Rajewski is currently engaged in various research projects that address emerging concerns in metabolic health and infectious diseases. His work on liver disease mechanisms and cardiovascular risk factors associated with obesity and metabolic syndrome aims to uncover better diagnostic markers and treatment pathways. A recent focus involves studying COVID-19’s impact on liver function and the interplay between viral infections and metabolic health, topics highly relevant in today’s healthcare landscape.

👥Professional Associations and Certifications: 

Dr. Rajewski’s memberships in prestigious medical associations, including the Polish Lipid Association and the Polish Association for the Study of Obesity, underscore his dedication to staying at the forefront of medical science. His certified expertise as a lipidologist and obesitologist enables him to approach health issues with a comprehensive understanding of lipid and metabolic disorders, enhancing the efficacy of treatments and preventive measures.

🏆Scholarships and Awards: 

Dr. Rajewski’s contributions to medicine have earned him numerous accolades, recognizing his achievements in research and clinical practice. These awards celebrate his innovation in metabolic research and his pivotal role in infectious disease management. His scholarship funding reflects a legacy of excellence and a commitment to advancing medical science.

📖Training & Workshops Attended:

In his pursuit of continual growth, Dr. Rajewski has attended a series of specialized workshops on bioinformatics, advanced diagnostics, and clinical applications in infectious disease management. These workshops equip him with cutting-edge skills that he applies to his daily work, benefiting patients and enhancing the training of his medical students.

💻Contributions to Bioinformatics and Clinical Research: 

A proficient bioinformatician, Dr. Rajewski integrates data science and computational tools in his research on metabolic diseases and infectious pathogens. By utilizing bioinformatics, he has been able to analyze complex datasets, leading to insights into genetic predispositions and disease progression. His ability to harness bioinformatics tools strengthens his work in both metabolic and infectious disease studies, positioning him at the cutting edge of medical research.

🎤Oral Presentations and Conferences: 

As a frequent presenter at national and international conferences, Dr. Rajewski shares his research findings with the medical community. His presentations cover topics like liver disease pathogenesis, metabolic syndrome treatments, and emerging infectious diseases. He contributes actively to knowledge exchange, with his lectures serving as valuable learning resources for both peers and students.

📊Key Tasks and Responsibilities as a Researcher:

In his research role, Dr. Rajewski coordinates multi-disciplinary teams, designing studies, and conducting extensive data analyses. His responsibilities include overseeing clinical trials and ensuring the ethical integrity of research protocols. His dedication to stringent research standards has led to significant findings that improve patient care protocols and inform public health strategies.

🌠Success Factors:

Dr. Rajewski attributes his success to his commitment to continuous learning, innovation, and collaboration. His ability to bridge theoretical research with practical applications in healthcare makes his contributions exceptionally valuable. Additionally, his leadership in the clinical setting exemplifies his holistic approach to healthcare, balancing research with direct patient care.

🔍Publications & Laboratory Experience:

Dr. Rajewski’s extensive laboratory experience includes advanced diagnostics in liver diseases, where he employs innovative techniques to diagnose and manage conditions like hepatitis and liver fibrosis. His publications detail his findings on the effectiveness of new biomarkers, offering insights that enhance both diagnostics and treatment options for liver and metabolic disorders.

🌐Conclusion: 

Dr. Paweł Rajewski’s career exemplifies a dedication to excellence in medicine, research, and public health. His multifaceted expertise in internal medicine, infectious diseases, and metabolic health has propelled him to the forefront of healthcare in Poland. Dr. Rajewski’s contributions are invaluable to the fields of hepatology and infectious disease, positively impacting patient care and advancing medical knowledge. Through his foundation, research, and clinical roles, he continues to shape the future of health sciences, creating a lasting legacy of compassion, knowledge, and innovation.

 

Top Notable Publications:

 

Hepatitis C Infection Is Not a Cardiovascular Risk Factor in Young Adults

Authors: Not listed; need to check for full author details.

Year: 2024

Citation: Biomedicines, 2024, 12(10), article 2400. DOI: 10.3390/biomedicines12102400.

Feasibility and Cardiometabolic Effects of Time-Restricted Eating in Patients with Metabolic Syndrome

Authors: Not listed; need to check for full author details.

Year: 2024

Citation: Nutrients, 2024, 16(12), article 1802. DOI: 10.3390/nu16121802.

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

Authors: Not listed; need to check for full author details.

Year: 2022

Citation: Journal of Clinical Medicine, 2022, 11(17), article 5193. DOI: 10.3390/jcm11175193.

The Dynamics of Changes in the Concentration of IgG against the S1 Subunit in Polish Healthcare Workers in the Period from 1 to 12 Months after Injection, Including Four COVID-19 Vaccines

Authors: Not listed; need to check for full author details.

Year: 2022

Citation: Vaccines, 2022, 10(4), article 506. DOI: 10.3390/vaccines10040506.

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

Authors: Not listed; need to check for full author details.

Year: 2022

Citation: Journal of Clinical Medicine, 2022, 11(2), article 379. DOI: 10.3390/jcm11020379.

Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines

Authors: Not listed; need to check for full author details.

Year: 2022

Citation: Vaccines, 2022, 10(1), article 99. DOI: 10.3390/vaccines10010099.

Pilot Clinical Trial of Time-Restricted Eating in Patients with Metabolic Syndrome

Authors: Not listed; need to check for full author details.

Year: 2021

Citation: Nutrients, 2021, 13(2), article 346. DOI: 10.3390/nu13020346.

Resveratrol’s Impact on Vascular Smooth Muscle Cells Hyporeactivity: The Role of Rho-Kinase Inhibition

Authors: Not listed; need to check for full author details.

Year: 2020

Citation: BioMed Research International, 2020, article 9012071. DOI: 10.1155/2020/9012071.

Zakażenie wirusem cytomegalii w praktyce klinicznej – diagnostyka, objawy i leczenie w świetle aktualnej wiedzy

Authors: Not listed; need to check for full author details.

Year: 2019

Citation: Forum Zakażeń, 2019, issue 4, article FZ2019042. DOI: 10.15374/FZ2019042.

Melatonin Supplementation Lowers Oxidative Stress and Regulates Adipokines in Obese Patients on a Calorie‐Restricted Diet

Authors: Not listed; need to check for full author details.

Year: 2017

Citation: Oxidative Medicine and Cellular Longevity, 2017, article 8494107. DOI: 10.1155/2017/8494107.

Lakshmanan Loganathan | Pharmacogenomics | Best Researcher Award

Dr. Lakshmanan Loganathan | Pharmacogenomics | Best Researcher Award 

Dr. Lakshmanan Loganathan, Micro Health Laboratories, India

Dr. Lakshmanan Loganathan is a Scientist ‘C’ and Scientific Coordinator at Micro Health Laboratories, India, with over nine years of research experience and three years in the diagnostics field. Specializing in computational biology, drug design, microbial genomics, medical genetics, and pharmacogenomics, he has successfully led numerous research projects and developed innovative methodologies. Dr. Loganathan has expertise in structure-based and ligand-based drug design, molecular dynamics, RT-PCR, and SNP studies. With a strong background in computational skills, project management, and scientific communication, he is dedicated to advancing human health through cutting-edge research.

Profile:

Scopus Profile 

Orcid Profile

Google Scholar

 

Education Qualification:

 

Dr. Lakshmanan Loganathan holds a Ph.D. in Bioinformatics from Alagappa University, Karaikudi (2022), where he conducted a highly commendable thesis on RAS and CYP gene polymorphisms in anti-hypertensive treatment. He also earned a PG Diploma in Structural Pharmacogenomics (2015) with the university’s top rank and an M.Sc. in Bioinformatics (2014), both from Alagappa University, achieving high commendations for his innovative research in molecular docking and genomics. Additionally, he holds a B.Sc. in Microbiology from Yadava Arts & Science, Madurai (2012).

Professional Experiences:

Dr. Lakshmanan Loganathan is a Scientist ‘C’ and Scientific Coordinator at Micro Health Laboratories in India, where he has been instrumental in designing and implementing innovative experiments to develop cost-effective diagnostic tests since November 2022. His career includes extensive experience as a Research Scholar at Alagappa University, where he published multiple academic papers and contributed to collaborative research projects. Previously, he held positions such as Lab Manager and Research Associate at Rainbow Children’s Medicare, where he assisted in developing a molecular genetics laboratory and managed the NABL accreditation process. His role as Manager of Lab Operations at SciGene Diagnostics involved overseeing various departments and establishing effective communication with key stakeholders. With a strong background in research, diagnostics, and technical documentation, Dr. Loganathan is dedicated to advancing medical science through innovative methodologies and quality assurance processes.

 Academic Merit & Awards :

Dr. Lakshmanan Loganathan has made significant contributions to the field of bioinformatics, receiving numerous accolades throughout his academic and professional journey. He participated in the UGC-Resource Networking Summer Training Program at Jawaharlal Nehru University in 2013 and was honored with a certificate of appreciation from the Prime Minister of India for his involvement in the Republic Day Parade in 2014. In recognition of his outstanding academic performance during his M.Sc. at Alagappa University, he was named the “Meritorious Student of the Year” for 2013 and received several scholarships, including the PMT & VOC merit scholarship. During his Ph.D. tenure from 2015 to 2020, he was awarded fellowships from DBT, MHRD, and RUSA. Dr. Loganathan also received the special prize for best poster presentation at the ICCIPS-2019 conference and was recognized as the “INTERNATIONAL BEST RESEARCHER” in bioinformatics at the IISTAC-2022 congress.

Thesis work:

Dr. Lakshmanan Loganathan has a robust academic background in bioinformatics, with a focus on microbiology and pharmacogenomics. He completed a six-month post-M.Sc. dissertation on “Identification of Vibrio harveyi through 16s rRNA sequencing” under the guidance of Dr. P. Srinivasan at Alagappa University. Additionally, he undertook a six-month postgraduate diploma project on “Identification of potent inhibitors against NS3 helicase protein of Zika virus,” supervised by Dr. M. Karthikeyan. Dr. Loganathan’s Ph.D. thesis, titled “Role of RAS and CYP Gene Polymorphisms in Anti-Hypertensive Treatment,” also under the supervision of Dr. Karthikeyan, was highly commended for its contributions to pharmacogenomics and computational studies.

Top Notable Publications:

Renin and CYP P450 gene variations significantly associated with essential hypertension: A prospective pharmacogenomics study

Authors: Loganathan, L., Carlus, S.J., Muthusamy, K.

Year: 2024

Journal: Gene Reports

Volume: 37

Article Number: 102023

Citations: 0

HTNpedia: A Knowledge Base for Hypertension Research

Authors: Loganathan, L., Jeyaraman, J., Muthusamy, K.

Year: 2024

Journal: Combinatorial Chemistry and High Throughput Screening

Volume: 27(5)

Pages: 745–753

Citations: 0

In silico prediction, molecular modeling, and dynamics studies on the targeted next-generation sequencing identified genes underlying congenital heart disease in Down syndrome patients

Authors: Carlus, F.H., Sujatha, L.B., Kumar, A.G., Muthusamy, K., Carlus, S.J., et al.

Year: 2023

Journal: Annals of Pediatric Cardiology

Volume: 16(4)

Pages: 266–275

Citations: 0

Theoretical investigation on known renin inhibitors and generation of ligand-based pharmacophore models for hypertension treatment

Authors: Loganathan, L., Sankar, J., Rajendran, K., Muthusamy, K.

Year: 2023

Journal: Journal of Biomolecular Structure and Dynamics

Citations: 1

Targeting renin receptor for the inhibition of renin angiotensin aldosterone system: An alternative approach through in silico drug discovery

Authors: Loganathan, L., Briget Kuriakose, B., Lobelle Sampayan, E., Muthusamy, K.

Year: 2022

Journal: Computational and Theoretical Chemistry

Volume: 1208

Article Number: 113541

Citations: 1

An in silico analysis of the impact of POLE mutations on cladribine docking

Authors: Loganathan, L., Al-Haidose, A., Ganesh Kumar, A., Carlus, S.J., Abdallah, A.M.

Year: 2022

Journal: European Review for Medical and Pharmacological Sciences

Volume: 26(20)

Pages: 7580–7593

Citations: 3

Mechanistic insights on nsSNPs on binding site of renin and cytochrome P450 proteins: A computational perceptual study for pharmacogenomics evaluation

Authors: Loganathan, L., Kuriakose, B.B., Mushfiq, S., Muthusamy, K.

Year: 2021

Journal: Journal of Cellular Biochemistry

Volume: 122(10)

Pages: 1460–1474

Citations: 17

In silico drug designing for the identification of promising antagonist hit molecules against bradykinin receptor

Authors: Selvaraj, M., Loganathan, L., Kumar Thirumalaisamy, P., Lobelle Sampayan, E., Muthusamy, K.

Year: 2021

Journal: Computational and Theoretical Chemistry

Volume: 1202

Article Number: 113334

Citations: 0

Virtual screening assisted discovery of novel natural products to inhibit the catalytic mechanism of Mycobacterium tuberculosis InhA

Authors: Jayaraman, M., Loganathan, L., Muthusamy, K., Ramadas, K.

Year: 2021

Journal: Journal of Molecular Liquids

Volume: 335

Article Number: 116204

Citations: 21

Computational study on cross-talking cancer signalling mechanism of ring finger protein 146, AXIN and Tankyrase protein complex

Authors: Loganathan, L., Natarajan, K., Muthusamy, K.

Year: 2020

Journal: Journal of Biomolecular Structure and Dynamics

Volume: 38(17)

Pages: 5173–5185

Citations: 7